Skip to main content

Table 1 Baseline characteristics

From: Malnutrition affects cholesterol paradox in coronary artery disease: a 41,229 Chinese cohort study

Characteristica Overall (N = 41,229) LDL-C < 1.8 mmol/L (N = 4863) LDL-C ≥ 1.8 mmol/L (N = 36,366) P value
Demographic characteristics
 Age, years 62.9 (10.6) 64.4 (10.8) 62.8 (10.6) < 0.001
  Age ≥ 75 years, n (%) 6036 (14.6) 929 (19.1) 5107 (14.0) < 0.001
 Male, n (%) 30,897 (74.9) 3725 (76.6) 27,172 (74.7) 0.005
Coexisting conditions
 PCI, n (%) 30,415 (73.8) 3433 (70.6) 26,982 (74.2) < 0.001
 AMI, n (%) 9182 (22.3) 805 (16.6) 8377 (23.0) < 0.001
 CHF, n (%) 3902 (9.5) 409 (8.4) 3493 (9.6) 0.008
 Hypertension, n (%) 23,217 (56.3) 3020 (62.1) 20,197 (55.5) < 0.001
 Diabetes mellitus, n (%) 11,097 (26.9) 1623 (33.4) 9474 (26.1) < 0.001
 CKD, n (%) 8635 (21.9) 1154 (24.8) 7481 (21.5) < 0.001
 Atrial fibrillation, n (%) 939 (2.3) 133 (2.7) 806 (2.2) 0.026
 COPD, n (%) 348 (0.8) 54 (1.1) 294 (0.8) 0.038
 Stroke, n (%) 2340 (5.7) 347 (7.1) 1993 (5.5) < 0.001
 Anaemia, n (%) 12,922 (32.3) 2079 (44.0) 10,843 (30.7) < 0.001
Laboratory examination
 Haematocrit 0.40 (0.05) 0.38 (0.05) 0.40 (0.05) < 0.001
 Lymphocyte, 109/L 1.94 (0.71) 1.95 (0.71) 1.83 (0.69) < 0.001
 Total cholesterol, mmol/L 4.60 (1.21) 4.78 (1.13) 3.24 (0.91) < 0.001
 HDL-C, mmol/L 1.00 (0.26) 1.01 (0.26) 0.93 (0.30) < 0.001
 LDL-C, mmol/L 2.85 (0.98) 1.47 (0.26) 3.04 (0.88) < 0.001
 Triglyceride, mmol/L 1.67 (1.23) 1.67 (1.09) 1.68 (1.96) 0.304
 Albumin, g/L 36.29 (4.25) 36.36 (4.22) 35.74 (4.44) < 0.001
Medicine
 RASi, n (%) 20,082 (49.6) 2199 (46.5) 17,883 (50.00) < 0.001
 β-blocker, n (%) 32,652 (80.6) 3776 (79.8) 28,876 (80.7) 0.131
 Statins, n (%) 38,300 (94.6) 4396 (92.9) 33,904 (94.8) < 0.001
Events
 All-cause death, n (%) 5257 (12.8) 778 (16.0) 4479 (12.3) < 0.001
  1. aData are presented as the mean value (standard deviation), median [interquartile range] or number of participants (percentage)
  2. Abbreviations: LDL-C Low-density lipoprotein cholesterol, PCI Percutaneous coronary intervention, AMI Acute myocardial infarction, CHF Congestive heart failure, CKD Chronic kidney injury, COPD Chronic obstructive pulmonary disease, HDL-C High-density lipoprotein cholesterol, RASi Renin angiotensin system inhibitor